A Phase I Trial of p28 (Cell Penetrating Peptide) in the Treatment of Refractory Solid Tumors.

Trial Profile

A Phase I Trial of p28 (Cell Penetrating Peptide) in the Treatment of Refractory Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs P28 peptide (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors CDG Therapeutics
  • Most Recent Events

    • 07 Jun 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 07 Jun 2011 Interim results were presented at the 47th Annual Meeting of the American Society of Oncology (ASCO-2011).
    • 24 May 2011 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top